

C-Path Rare/Orphan and Pediatric Disease Programs Q3 2025 Newsletter Now Available

Welcome to the Rare/Orphan and Pediatric Disease Programs quarterly newsletter. In between major announcements, webinars and meetings, this communication serves to update you on the latest developments within C-Path's rare/orphan and pediatrics disease programs and the RDCA-DAP platform. Of note, in the past quarter, C-Path's Critical Path for Alpha-1 Antitrypsin Deficiency (CPA-1), hosted a recent [patient-focused drug development workshop](#). None of C-Path's advancements are possible without the participation of our members, collaborators and data contributors.

[Read the newsletter here](#)